Orexigen Therapeutics, a biopharmaceutical company, is focused on treating obesity. Contrave, Orexigen’s lead product candidate, has completed Phase III clinical trials, and a New Drug Application has been submitted and reviewed by the U.S. Food and Drug Administration. The company has additionally reached an agreement with the FDA on a Special Protocol Assessment (SPA) for the Light Study, which is the Contrave cardiovascular outcomes trial. For more information, visit the company’s Web site at www.orexigen.com.

The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. Each year the annual event provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. For more information on Biotechnology Industry Organization (BIO), visit www.bio.org.

Let us hear your thoughts below: